On April 1, 2022 Fortress Biotech, Inc. (NASDAQ: FBIO) ("Fortress"), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, reported a two-day summit hosted by the B. Riley Securities’ Healthcare Equity Research team, that will feature multiple programs from Fortress’ diversified pipeline (Press release, Fortress Biotech, APR 1, 2022, View Source [SID1234611356]). The events will be held virtually on Tuesday, April 5, and Wednesday, April 6, 2022, beginning at 1:00 p.m. ET each day.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Registration link and webcast information:

Please click here to register for the event.
Following each event, the webcast will be available on the News / Events page, located within the Investors section of Fortress’ website, View Source, for approximately 30 days.
Agenda:

Day One: Tuesday, April 5, 2022 (1:00 p.m. – 3:00 p.m. ET)

1:00 p.m. ET – Opening Remarks and Fortress Strategy

Lindsay Rosenwald, M.D., Chairman, President & Chief Executive Officer of Fortress Biotech; Mayank Mamtani, Head of HC Research, B. Riley Securities

1:30 p.m. ET – Panel #1 – Journey Medical Corporation (NASDAQ: DERM)

Claude Maraoui, Co-Founder, President & Chief Executive Officer; Ernie De Paolantonio, Chief Financial Officer; Ramsey Alloush, General Counsel

2:00 p.m. ET – Panel #2 – Cyprium Therapeutics

Charles Buchen, M.D., Chief Business Officer; Lung Yam, M.D., Ph.D., President & Chief Scientific Officer

2:30 p.m. ET – Panel #3 – UR-1 Therapeutics

Raymond Zheng, Ph.D., President & Chief Scientific Officer; Scott Baumgartner, M.D., Interim Chief Medical Officer

Day Two: Wednesday, April 6, 2022 (1:00 p.m. – 3:00 p.m. ET)

1:00 p.m. ET – Fortress Strategy – Execution and Value Generation

Lindsay Rosenwald, M.D., Chairman, President & Chief Executive Officer of Fortress Biotech

1:30 p.m. ET – Panel #1 – Mustang Bio (NASDAQ: MBIO)

Manuel Litchman, M.D., President & Chief Executive Officer; Knut Niss, Ph.D., Chief Technology Officer; Bruce Dezube, M.D., Senior Vice President, Head of Clinical Development; Eliot Lurier, C.P.A., Interim Chief Financial Officer

2:15 p.m. ET – Panel #2 – Checkpoint Therapeutics (NASDAQ: CKPT)

James F. Oliviero, President & Chief Executive Officer; Garrett Gray, Chief Financial Officer